View in EDS

Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.

Saved in:
Bibliographic Details
Title: Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.
Authors: Adeshara K; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lithovius R; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mutter S; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Harjutsalo V; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lehto M; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Groop PH; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi., Sandholm N; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. niina.sandholm@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. niina.sandholm@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. niina.sandholm@helsinki.fi.
Corporate Authors: FinnDiane Study Group
Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Dec 12; Vol. 25 (1), pp. 13. Date of Electronic Publication: 2025 Dec 12.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41387868
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Adeshara+K%22">Adeshara K</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Lithovius+R%22">Lithovius R</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Mutter+S%22">Mutter S</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Harjutsalo+V%22">Harjutsalo V</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Lehto+M%22">Lehto M</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Groop+PH%22">Groop PH</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.<br /><searchLink fieldCode="AU" term="%22Sandholm+N%22">Sandholm N</searchLink>; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. niina.sandholm@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. niina.sandholm@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. niina.sandholm@helsinki.fi.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22FinnDiane+Study+Group%22">FinnDiane Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101147637%22">Cardiovascular diabetology</searchLink> [Cardiovasc Diabetol] 2025 Dec 12; Vol. 25 (1), pp. 13. <i>Date of Electronic Publication: </i>2025 Dec 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Observational Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101147637 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1475-2840 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214752840%22">14752840 </searchLink><i>NLM ISO Abbreviation: </i>Cardiovasc Diabetol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41387868
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12933-025-03017-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 13
    Titles:
      – TitleFull: Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Adeshara K
      – PersonEntity:
          Name:
            NameFull: Lithovius R
      – PersonEntity:
          Name:
            NameFull: Mutter S
      – PersonEntity:
          Name:
            NameFull: Harjutsalo V
      – PersonEntity:
          Name:
            NameFull: Lehto M
      – PersonEntity:
          Name:
            NameFull: Groop PH
      – PersonEntity:
          Name:
            NameFull: Sandholm N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 12
              Text: 2025 Dec 12
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1475-2840
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cardiovascular diabetology
              Type: main
ResultId 1